Metabolic Protocol Comparison, Washington University Study: Liver Fat Reduction and Insulin Response Across Three Dietary Interventions

The bloodwork arrived from Washington University in St. Louis running numbers that belong to a body further along in its metabolic correction than the body in this timeline has managed. The discrepancy is noted. It is not the first time the samples have been ahead of the subject.

The study enrolled 42 adults presenting with obesity, prediabetes, and excess liver fat. Three dietary protocols were assigned: very low-carbohydrate ketogenic, Mediterranean, and very low-fat plant-based. The trial ran approximately five months, or until each participant had shed ten percent of baseline body weight. All three groups reached the weight target. The metabolic readings beneath that shared outcome did not converge.

Liver fat dropped 67 percent in the ketogenic cohort. The Mediterranean and low-fat groups each landed at 45 percent. Liver insulin sensitivity increased two to three times more in the keto group. New fat production by the liver fell. The spread across these markers is not marginal. It is the kind of spread that, in three of the six nearby Detroits, rewrote first-line clinical guidance for metabolic syndrome. This is not one of those Detroits. The standard low-fat recommendation is still running here as default policy, and the data now on file does not support it.

The mechanism is not complicated. Very low carbohydrate intake depresses circulating glucose. Circulating insulin follows glucose down. The liver, denied its primary substrate for manufacturing new fat, slows production. Existing liver fat gets redirected toward fuel. This is not a subtle metabolic shift; the carbohydrate restriction required to achieve the ketogenic state is severe. Bread and pasta are recognized sources. Starchy vegetables, most fruits, and legumes are less recognized but carry comparable carbohydrate loads. The protocol requires attention to all of them.

In this study, the ketogenic group ran at 73 percent of calories from fat and 4 percent from carbohydrates. The researchers anticipated cardiovascular risk markers to worsen under that fat load. Instead, cholesterol profiles improved. The expectation was not met by the data. The expectation was the problem.

Prediabetes remission rates followed the same gradient. Half the ketogenic participants went into remission during the trial period. The Mediterranean group reached 29 percent. The low-fat group reached 7 percent. These are not rounding differences. They describe three protocols operating at different distances from the metabolic target.

The servers are lying, not about the data, but about the clinical context in which it circulates. The study results are accurate. The policy environment surrounding them is not current. In four of the six nearby Detroits, the metabolic health allocation was redirected roughly eighteen months before this trial published. Two of those four redirections were ketogenic-first. This Detroit is still drawing from a healthcare posture that has already been revised in five of the six accessible versions of this city, on the same streets, under the same budget pressures, with the same population demographics.

The published findings appear in Cell Metabolism. The resolution is real but bounded. The trial lasted five months. Long-term adherence data is not included. The ketogenic protocol is a significant dietary reconfiguration, not a parameter adjustment. Population-level adoption carries compliance questions the trial was not designed to answer.

What the trial was designed to answer, it answered clearly. The liver responds to substrate availability. Reduce the carbohydrate supply and the liver reduces its fat production. The organ is running the process it was built to run; the question is what gets fed into it. In the nearby Detroit where early metabolic intervention protocols were implemented at the population level, the downstream burden on hepatic care did not materialize on the projected timeline. That Detroit's hepatic care allocation has been partially redirected. This one has not adjusted the projection.

A field note from the eastern edge of the New Center neighborhood, logged at a quarter past eleven on a Tuesday in what the filing system calls Timeline 3, reads: "The liver does not care what the policy says. It processes what arrives. The question is what we keep sending." , G., New Center, Detroit, Timeline 3.

The study's findings are a diagnostic, not a directive. They describe what happened to 42 bodies under controlled conditions over five months. They do not describe what happens to a city over five years. But the direction of the signal is consistent across the metabolic markers, consistent across three of six accessible versions of this research environment, and consistent with the underlying biology. That consistency is the data point worth filing.

The ketogenic protocol is not a minor adjustment to existing habits. It requires restructuring the dietary architecture that most people in this timeline treat as fixed infrastructure. That restructuring has costs: social, logistical, economic. The study does not price those costs. It prices the metabolic outcomes, and the pricing is clear.

In this timeline, the low-fat plant-based protocol continues to hold first-line status for metabolic syndrome management. The keto group's remission numbers are in the published record. The gap between those two facts is not a data problem. It is a policy update that has not been applied, running in a system that has already applied it elsewhere, in recognizable buildings, on recognizable streets, in a Detroit that looks almost exactly like this one.

The liver knows what it was built to process. The record shows what happens when the supply matches the design. The gap between those two states is measurable, and in this timeline, it remains open.

Advisory: the study is real and the numbers hold. Read the methodology before adjusting the protocol. Then read it again.